CHUGAI PHARMACEUTICAL CO., LTD.

DelveInsight's 'Hepatocellular Carcinoma Pipeline Insight 2024' report details 90+ companies developing 95+ pipeline drugs for HCC, with therapies in various stages of clinical development, including collaborations and regulatory approvals.

Halozyme Therapeutics announces argenx has nominated four new targets for ENHANZE® drug delivery tech, bringing the total to six, including FcRn. argenx to pay Halozyme $30 million upfront and potential future milestone payments up to $85 million per target.

S.B., A.D., T.J.F., I.M.G., L.G., R.K.J., G.K., J.M.L., G.V.L., K.P.-J., H.I.S., J.T., R.R.W., M.W., Y.L.W. have disclosed various financial interests, including funding, advisory roles, patents, and equity. C.M.B., E.B., M.W.B., and K.P. declare no competing interests.

Chugai Pharmaceutical Co., Ltd. announces MHLW approval of Evrysdi® Dry Syrup 60 mg for pre-symptomatic SMA and additional dosage for infants under 2 months, based on the RAINBOWFISH study. Evrysdi, the only oral treatment for SMA, aims to maximize treatment effects by initiating intervention early.

The FDA approved OCREVUS ZUNOVO™, a twice-a-year subcutaneous injection for relapsing and primary progressive multiple sclerosis, offering more treatment options. This approval is supported by a decade of safety and efficacy data from Ocrevus® IV, with over 350,000 people treated globally. OCREVUS ZUNOVO™ provides flexibility in treatment administration, potentially expanding access to those without IV infrastructure.

FDA approves Roche's OCREVUS ZUNOVO™ with Halozyme's ENHANZE® for RMS and PPMS, offering a 10-minute subcutaneous injection.

Roche received FDA approval for OCREVUS ZUNOVO™, a subcutaneous injection using Halozyme's ENHANZE® technology for RMS and PPMS, offering a 10-minute, twice-a-year treatment.

Halozyme announces FDA approval for Roche's Tecentriq Hybreza™, a subcutaneous anti-PD-(L)1 immunotherapy using ENHANZE® technology, offering faster administration and broader treatment options for lung, liver, skin, and soft tissue cancers.

FDA approves Roche's Tecentriq Hybreza™, a subcutaneous anti-PD-(L)1 immunotherapy using Halozyme's ENHANZE® technology, reducing injection time to 7 minutes from 30-60 minutes for IV infusion, available for adult indications of IV Tecentriq® in the U.S.